SCHEMBL6104155

SCHEMBL6104155

COC(=O)C1CCN(c2ccc(Br)cc2/C=C(\C)C(=O)OC(C)(C)C)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.40
SMN1; SMN2 Q16637 2/20 0.38
ALDH1A1 P00352 1/20 0.38
HTT P42858 1/20 0.38
HSD11B1 P28845 1/20 0.36
BACE1 P56817 2/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
RBP4 P02753 1/20 0.34
USP30 Q70CQ3 1/20 0.34
NOTUM Q6P988 1/20 0.34
OPRK1 P41145 1/20 0.34
KEAP1 Q14145 1/20 0.34
PIM1 P11309 1/20 0.33
PIM3 Q86V86 1/20 0.33
PIM2 Q9P1W9 1/20 0.33
NSD2 O96028 1/20 0.33
MAPK1 P28482 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
GABRA1 P14867 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6104166 1.00 MAPT (0.40) MAPTSMN1; SMN2ALDH1A1HTTHSD11B1
SCHEMBL6103200 0.82 SMN1; SMN2 (0.44) MAPTSMN1; SMN2ALDH1A1HTTHSD11B1
SCHEMBL6103054 0.71 LIPG (0.37) OPRK1
SCHEMBL6103060 0.71 LIPG (0.37) OPRK1
SCHEMBL23119683 0.71 MAPT (0.53) MAPTSMN1; SMN2ALDH1A1HTTMEN1
SCHEMBL15919657 0.70 NOTUM (0.46) MAPTSMN1; SMN2ALDH1A1HTTKMT2A
SCHEMBL6104033 0.69 CHEK1 (0.41) ALDH1A1RBP4NOTUMOPRK1
SCHEMBL6105619 0.69 GAA (0.42) MAPTSMN1; SMN2ALDH1A1HTTRBP4
SCHEMBL6104028 0.69 CHEK1 (0.41) ALDH1A1RBP4NOTUMOPRK1
SCHEMBL6105614 0.69 GAA (0.42) MAPTSMN1; SMN2ALDH1A1HTTRBP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160864-A1 Acrylamide derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-07-20 US disclosed
EP-1593673-A1 ACRYLAMIDE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Pharmaceutical Company Limited (JP) 2005-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160864-A1 Acrylamide derivative, process for producing the same, and use CCR5, MSR1, CCR2 MAPT 4646/4885SMN1; SMN2 2871/4885ALDH1A1 1414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.